Articles tagged with Oncology
A recent study found that cannabis may reduce opioid use among commercially insured patients with cancer diagnoses, indicating potential benefits for pain management. However, further research is needed to confirm the efficacy of cannabis as a treatment for cancer-related pain.
Mikkael Sekeres has been elected to the Executive Committee of the American Society of Hematology (ASH), a four-year term starting after the 2025 ASH Annual Meeting. He will help strengthen the organization's mission in shaping the future of hematology.
Researchers identified 5.05% of individuals carrying pathogenic variants in key cancer susceptibility genes, highlighting a significant association between these genetic variations and increased cancer risk. The study suggests that more extensive genetic screening for these genes may be warranted to identify high-risk individuals.
Chronic stress reprograms tumor microenvironment, fueling cancer development and metastasis through stress-activated signaling pathways. Stress management may now be part of precision oncology, suggesting potential interventions like beta-blockers and behavioral approaches.
The ESMO Congress 2025 will cover key topics including precision oncology, antibody-drug conjugates in breast cancer, dose optimisation strategies, new treatment modalities for melanoma, and immunotherapy-based approaches across various cancer settings. Promising Phase-3 studies on ADCs in bladder and lung cancer are also expected.
Researchers developed a latex-based tissue adhesive to prevent seroma formation and prolonged lymphorrhea after axillary dissection. The study found that the adhesive significantly reduced wound exudate volume and allowed patients to be discharged earlier, with no complications reported.
Researchers found that patients with stage III or IV cancer who quit smoking lived significantly longer than those who continued smoking, with a two-fold lower rate of all-cause mortality. The study's findings emphasize the crucial role of smoking cessation support as part of standard cancer care.
Ochsner Health's Genetic Wellness Assessment is an innovative screening tool that helps identify individuals at risk for hereditary cancers. The assessment evaluates personal and family history to provide personalized cancer screening and prevention plans.
ACTM-838, a novel bacterial immunotherapy, enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity. The therapy shows durable anti-tumor efficacy and synergizes with anti-PD1 drugs, improving outcomes in treatment-resistant tumor models.
Researchers found that smoking and biological sex shape how normal cells evolve in healthy bladder tissue, with certain mutations gaining an advantage to expand into clones. This study offers new insights into cancer risk and prevention by providing a way to understand tissue evolution and identify early warning signs.
The Association for Molecular Pathology has created a standardized biomarker report template to simplify complex molecular profiling data presentation to oncologists and healthcare providers. The template includes guidelines for clear formatting, therapeutic guidance, and references to clinical practice guidelines.
Paul N. Staats, MD, has been appointed Chair of the University of Maryland School of Medicine's Department of Pathology, overseeing clinical services to multiple hospitals and laboratories. He will drive partnerships and expand outpatient laboratory services.
St. Jude recognized as one of the top 10 pediatric cancer hospitals in US, consistently earning a place among the nation's best for pediatric oncology. The hospital maintains top survival rates for childhood cancers and drives progress in treatment and survivorship.
The NCCN Guidelines Navigator now covers treatment for over a dozen cancer types, including hereditary risk assessment, providing seamless navigation and search capabilities. The new format aims to improve treatment decision-making based on the latest evidence and expert-consensus.
A study of 42,451 patients found that those whose credit scores dropped after a cancer diagnosis faced a significantly higher risk of mortality. The researchers also identified high-risk demographics and socioeconomic factors associated with financial toxicity.
Researchers found that rectal bleeding increases the odds of a colorectal cancer diagnosis by 8.5 times in patients under 50, highlighting the need for symptom-driven care and lifestyle modifications to reduce the risk. The study analyzed 443 patients and identified no family history as a factor in early-onset colorectal cancers.
A topical formulation has been shown to reduce the incidence of hand-foot neuropathy in cancer patients undergoing chemotherapy, improving quality of life. The cream, developed at UMH, acts directly on neurosensory pain receptors, reducing hypersensitivity and tolerance to chemotherapy.
The WIN Symposium, featuring oncology experts, aims to accelerate the translation of research into clinical practice through keynote lectures and networking opportunities. The event is part of the Advancing Precision Medicine (APM) Annual Conference 2025.
A team led by Carnegie Mellon researchers has developed an innovative at-home urine test to detect over 30 types of early-stage solid tumors. The technology, combining synthetic biology and nucleic acid nanotechnology, aims to provide a precise and convenient way to screen for cancer.
Researchers at Sylvester Comprehensive Cancer Center are pioneering innovative approaches to treating complex movement disorders with advanced imaging and radiosurgery techniques. The new era of functional radiosurgery enables precise treatment without invasive procedures.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
An AI model successfully automates lymph node segmentation and extranodal extension classification from pretreatment CT scans in HPV-associated oropharyngeal carcinoma. Predicted extranodal extension is independently associated with worse oncologic outcomes, highlighting the potential for improved treatment planning.
A new study discovers a previously unknown long noncoding RNA, EUDAL, that helps oral cancer cells survive chemotherapy by permanently activating the epidermal growth factor receptor. This RNA molecule blocks the cellular tagging system, allowing EGFR to remain active and promote autophagy in cancer cells.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer. The study included a larger patient population than previously published randomized studies and followed these patients for much longer.
A phase III trial suggests that post-operative radiation therapy can reduce cancer recurrence in patients with high-risk disease. Patients who received radiation experienced significantly fewer pelvic recurrences and improved locoregional recurrence-free survival compared to those who did not receive radiation.
A phase III trial comparing proton and photon radiation therapy for breast cancer found that patients report equally strong health-related quality of life with either treatment. Patients treated with protons were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
A phase III trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. Excellent tumor control and fewer long-term side effects were seen with both treatments.
A recent study suggests that the rise in early-onset cancer incidence in the US population may not be as significant as initially thought. Much of the increase is attributed to increased diagnostic scrutiny and over-diagnosis, rather than a genuine rise in clinically meaningful cancer cases.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
A study has identified KIMA, a genomic signature associated with a poor treatment response in HR+/HER2- breast cancer patients. The signature, composed of nine genes, can predict disease progression and overall survival, enabling personalized therapy selection.
A new robot-assisted bronchoscope has been shown to diagnose tiny lung tumors in hard-to-reach areas with over 84% success rate, more than three times higher than traditional methods. The technology enables accurate diagnosis in patients where conventional bronchoscopy offers no viable option.
A new study suggests that low-dose aspirin can prevent cancer in older adults based on individual characteristics. The analysis found varying treatment effects among participants, highlighting the need for personalized approaches to cancer prevention.
A study by University of Florida researchers found that 93% of new cancer patients are exposed to at least one type of misinformation about cancer treatments. The most common sources were second-hand information from friends, family, social media, and news outlets. The study suggests that clinicians should assume their patients have be...
New research reveals that zebrafish models can help guide clinical decision-making in real-time for challenging pediatric cancer cases. The study shows that pre-clinical zebrafish models accurately predicted responses to 11 of 12 treatment regimens, providing robust and actionable treatment response data.
A large-scale randomized trial will examine whether AI supports radiologists in interpreting mammograms more accurately, reducing unnecessary callbacks and anxiety. The PRISM Trial, led by UCLA, aims to inform future policy decisions and best practices in breast cancer screening.
A new study from the University of California - Los Angeles Health Sciences suggests that regular mammograms may still offer significant benefits for women in their 80s. The study found that screened women were more likely to have surgery to remove the tumor and had a lower risk of cancer returning and dying compared to unscreened women.
A cohort study reveals oral bacteria and fungi as significant risk factors for pancreatic cancer development. The findings suggest that oral microbiota may serve as biomarkers to identify individuals at high risk of pancreatic cancer, potentially contributing to personalized prevention strategies.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.
A large-scale population study found that oxaliplatin benefits only younger stage III patients, with no added survival benefit for those over 70. The study suggests using an age threshold to make evidence-based choices about chemotherapy.
A new study shows that remote perioperative monitoring significantly improves recovery for cancer surgery patients, with a 6% greater functional recovery rate by day 14 after surgery. The study also found fewer major complications and improved symptom management.
A cohort study suggests nicotinamide reduces skin cancer risk, with greatest effect seen after initial skin cancer diagnosis, indicating potential chemopreventive properties of the vitamin B3 derivative
A growing body of research links environmental pollutants to worsened health and shorter life spans in childhood cancer survivors. The study found that only 25% of pediatric oncology providers felt comfortable discussing environmental pollutant impacts with patients.
These rare tumors often present with aggressive behavior, early metastasis, and resistance to chemotherapy and radiotherapy. Early detection and disease staging are key factors associated with improved survival.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
A $1.7M Department of Defense grant funds the Convergent Science Virtual Cancer Center, strengthening expertise in cancer risks faced by military personnel and their families. The center provides personalized mentorship, immersive workshops, and non-traditional educational opportunities to improve patient outcomes across various cancers.
A new study highlights why kids' brain tumors need therapies designed for their unique biology, pointing to engineered immune cells and cancer vaccines as promising approaches. The review emphasizes the need for targeted treatments that recognize and fight childhood brain tumor differences.
A consortium led by the University of Southampton aims to advance cutting-edge treatments for lung cancer, blood cancers, and chronic inflammation. The ON-TRACT project will train researchers in academic, industrial, and clinical settings to develop safer and more effective treatments.
A recent study published in the Lancet Primary Care tracked over 4,800 patients referred to the SCAN Pathway, a cancer diagnosis pathway designed for patients with non-specific symptoms. The study found that early diagnosis of cancers can save thousands of lives and reduce treatment costs for the NHS.
Researchers evaluated a tool based on NCCN Guidelines to identify high-risk medications and their association with frailty and outcomes in over 380,000 older adults diagnosed with cancer. The study found that each additional high-risk medication increased the odds of being mildly or moderately-to-severely frail by 66%.
Researchers found that lung cancer cells can form functional synapses with neurons, supporting their growth and survival. Disrupting glutamate signalling led to lower tumour burden and longer survival in experimental mice, highlighting promising therapeutic targets.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
Experts weighed in on the current state of artificial intelligence (AI) in cancer care, noting both its potential for improving efficiency and its challenges. Many expressed excitement over AI's possibilities for helping support an overburdened oncology workforce and accelerating the pursuit of new cures.
Researchers developed photo-inducible binary interaction tools (PhoBITs) to precisely control gene expression, cell signaling, and immune responses. PhoBITs enable targeted treatment with minimal side effects, opening new avenues for cancer therapy, immunotherapy, and regenerative medicine.
Phoenix SENOLYTIX and MD Anderson Cancer Center announced a cross-licensing agreement to further develop inducible switch technologies for use in cell and gene therapies. The partnership will enhance the development of these technologies, which can be used as safety features to regulate cell therapy activity.
The ASTRO's 2025 Annual Meeting will feature pivotal studies in radiation medicine, highlighting advances in radiopharmaceutical therapy and new indications for low-dose radiation therapy. The meeting will also explore cutting-edge techniques for prostate, breast, lung, and other common cancers.
Researchers discovered that disrupting protein quality control slows tumor growth in rhabdomyosarcoma, a rare and aggressive cancer primarily affecting children. The treatment, which targets the proteostasis network, significantly slowed or stopped tumor growth in mice implanted with human RMS tumors.
A study published in Oncoscience found that over 60% of oncology healthcare professionals in Morocco showed signs of severe burnout, with emotional exhaustion being the key factor. The study highlights the need for urgent institutional changes to support healthcare workers and improve work environments.